Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
August 29, 2023
Assignees:
SIB Swiss Institute of Bioinformatics, CHUV—Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Ludwig Institute for Cancer Research Ltd
Inventors:
Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao